Combination of Nanovectorized siRNA Directed against Survivin with Doxorubicin for Efficient Anti-Cancer Activity in HER2+ Breast Cancer Cells

Combination of Nanovectorized siRNA Directed against Survivin with Doxorubicin for Efficient Anti-Cancer Activity in HER2+ Breast Cancer Cells

According to Globocan 2020, breast cancer is considered one of the most common cancers affecting women and is one of the leading causes of death in over 100 countries. The available classical treatment options do not always give satisfactory outcomes, and some patients develop resistance to these tr...

Full description

Bibliographic Details
Main Authors: Sahar Eljack, Emilie Allard-Vannier, Yoann Misericordia, Katel Hervé-Aubert, Nicolas Aubrey, Igor Chourpa, Areeg Faggad, Stephanie David
Format: Article
Language:English
Published: MDPI AG 2022-11-01
Series:Pharmaceutics
Subjects:
siRNA
targeted nanovector
HER2+
Doxorubicin
Survivin
Online Access:https://www.mdpi.com/1999-4923/14/11/2537

Similar Items

Similar Items